Drug Profile
SPARC 1613
Alternative Names: SPARC-1613Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Sun Pharma Advanced Research Company
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Recurrent) in India (IV, Infusion)
- 04 Oct 2018 Sun Pharma Advanced Research Company completes a phase I trial in Breast cancer (Recurrent, Metastatic disease) in India (NCT03109249)